Oncolytic Virus Manufacturing

Virus manufacturing for oncolytic therapies

ABL has increased capacity, increased scale, and diversified capabilities to offer a variety of suspension and adherent production platforms to manufacture our clients’ novel oncolytic therapies.

Global capabilities include:

  • Oncolytic viral vector manufacturing — adherent & suspension platforms:
    • Vaccinia
    • MVA
    • HSV
    • Adenovirus
    • Others
  • Aseptic processing for drug substance & drug product
  • US- & EU-based GMP operations
  • Global supply for Phase I – III & product approval
  • Comprehensive QC release & stability testing
  • Process & analytical development, qualification, characterization & validation
  • 10+ years proven technical & regulatory track record in oncolytic virotherapies
Bioreactor GMP manufacturing upstream

ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

 

ABL, Inc. (ABL), a global contract manufacturing organization that advances leading vaccines and therapies from clinical development to the commercial market, is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe SAS (ABL Europe), of a 6,500 m2 GMP manufacturing site located in Lyon, France.

Contact us now to speak with one of our experts:

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.